Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Holders of 5% or more of GLUE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Monte Rosa Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 13G/A | 10.50%8.86M shares | +3.00 ppfrom 7.50% | Feb 10, 20228 filings | Jul 8, 2026 | SEC |
| Baker Bros. Advisors LP | 13G/A | 9.99%8.88M shares | +3.29 ppfrom 6.70% | Feb 14, 20243 filings | May 15, 2026 | SEC |
| Dimension Capital I, L.P. | 13G/A | 8.10%6.51M shares | −0.60 ppfrom 8.70% | Oct 3, 20253 filings | Apr 22, 2026 | SEC |
| New Enterprise Associates 17, L.P. | 13D/A | 7.90%6.69M shares | −1.80 ppfrom 9.70% | Jul 12, 20215 filings | Jul 6, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 6.30%5.09M shares | +0.40 ppfrom 5.90% | Jan 31, 20254 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.30%3.84M shares | New | Feb 4, 20251 filing | Feb 4, 2025 | SEC |
| TCG Crossover GP II, LLC | 13G/A | 5.50%4.62M shares | −1.70 ppfrom 7.20% | Oct 17, 20252 filings | May 15, 2026 | SEC |
| Vestal Point Capital, LP | 13G | 5.40%4.60M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
58 Schedule 13D and 13G filings on Monte Rosa Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:23 PM ET | Suvretta Capital Management, LLCand 2 others | 13G/A | 4.20%3.55M shares | −1.30 ppfrom 5.50%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20264:10 PM ET | Vestal Point Capital, LPand 1 other | 13G | 5.40%4.60M shares | New | Jun 30, 2026 | SEC |
| Jul 8, 202611:28 AM ET | Price T Rowe Associates Inc | 13G/A | 10.50%8.86M shares | +3.00 ppfrom 7.50% | Jun 30, 2026 | SEC |
| Jul 6, 20265:51 PM ET | New Enterprise Associates 17, L.P.and 11 others | 13D/A | 7.90%6.69M shares | −1.80 ppfrom 9.70% | Jul 1, 2026 | SEC |
| May 15, 20264:24 PM ET | TCG Crossover GP II, LLCand 4 others | 13G/A | 5.50%4.62M shares | −1.70 ppfrom 7.20% | Mar 31, 2026 | SEC |
| May 15, 20264:18 PM ET | Baker Bros. Advisors LPand 3 others | 13G/A | 9.99%8.88M shares | +3.29 ppfrom 6.70% | Mar 31, 2026 | SEC |
| May 15, 20264:10 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 6.30%5.09M shares | +0.40 ppfrom 5.90% | Mar 31, 2026 | SEC |
| Apr 22, 20265:40 PM ET | Dimension Capital I, L.P.and 8 others | 13G/A | 8.10%6.51M shares | −0.60 ppfrom 8.70% | Mar 31, 2026 | SEC |
| Mar 19, 20264:05 PM ET | New Enterprise Associates 17, L.P.and 11 others | 13D/A | 9.70%7.80M shares | – | Mar 17, 2026 | SEC |
| Feb 17, 20264:14 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 5.90%3.84M shares | −3.30 ppfrom 9.20% | Dec 31, 2025 | SEC |
| Feb 17, 20264:10 PM ET | Baker Bros. Advisors LPand 3 others | 13G/A | 6.70%4.35M shares | – | Dec 31, 2025 | SEC |
| Jan 21, 202611:59 AM ET | Dimension Capital I, L.P.and 6 others | 13G/A | 8.70%5.66M shares | +1.00 ppfrom 7.70% | Dec 31, 2025 | SEC |
| Jan 9, 20264:19 PM ET | Versant Venture Capital VI, L.P.and 5 others | 13D/A | 3.40%2.24M shares | −1.70 ppfrom 5.10%Below 5% | Jan 7, 2026 | SEC |
| Nov 14, 202512:19 PM ET | Price T Rowe Associates Inc | 13G/A | 7.50%4.64M shares | – | Sep 30, 2025 | SEC |
| Nov 14, 20259:07 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 0.00%0 shares | −6.10 ppfrom 6.10%Below 5% | Sep 30, 2025 | SEC |
| Nov 12, 20254:13 PM ET | Versant Venture Capital VI, L.P.and 5 others | 13D/A | 5.10%3.33M shares | – | Nov 10, 2025 | SEC |
| Oct 31, 202511:04 AM ET | Vanguard Group Inc | 13G/A | 4.83%2.99M shares | −0.30 ppfrom 5.13%Below 5% | Sep 30, 2025 | SEC |
| Oct 17, 20254:29 PM ET | TCG Crossover GP II, LLCand 4 others | 13G | 7.20%4.43M shares | New | Oct 10, 2025 | SEC |
| Oct 3, 202512:19 PM ET | Dimension Capital I, L.P.and 6 others | 13G | 7.70%4.76M shares | New | May 16, 2024 | SEC |
| Aug 14, 20257:10 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 6.10%3.73M shares | −1.00 ppfrom 7.10% | Jun 30, 2025 | SEC |
| Jun 6, 202510:03 AM ET | FMR LLCand 1 other | 13G/A | 2.80%1.75M shares | –Below 5% | May 30, 2025 | SEC |
| May 15, 20254:33 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.20%5.66M shares | +2.00 ppfrom 7.20% | Mar 31, 2025 | SEC |
| Apr 16, 20255:30 PM ET | Suvretta Capital Management, LLCand 2 others | 13G | 5.50%3.36M shares | New | Apr 9, 2025 | SEC |
| Feb 14, 20259:30 AM ET | Avoro Capital Advisors LLCand 1 other | 13G/A | 7.10%4.34M shares | – | Dec 31, 2024 | SEC |
| Feb 4, 20253:45 PM ET | BlackRock, Inc. | 13G | 6.30%3.84M shares | New | Dec 31, 2024 | SEC |
| Jan 31, 20256:43 PM ET | Biotechnology Value Fund L Pand 9 others | 13G | 7.20%4.39M shares | New | Jan 24, 2025 | SEC |
| Jan 30, 20259:58 PM ET | Vanguard Group Inc | 13G | 5.13%3.16M shares | New | Dec 31, 2024 | SEC |
| Nov 14, 2024 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Nov 12, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Oct 30, 2024 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Sep 24, 2024 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Aug 12, 2024 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Aug 12, 2024 | New Enterprise Associates 17, L.P. | 13D/AOld format | – | – | – | SEC |
| May 13, 2024 | New Enterprise Associates 17, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 10, 2024 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 14, 202411:22 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Baker Bros. Advisors LP | 13GOld format | – | New | – | SEC |
| Feb 14, 2024 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Nov 9, 2023 | Versant Venture Capital VI, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 3, 20234:27 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Feb 14, 2022 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Avoro Capital Advisors LLC | 13GOld format | – | New | – | SEC |
| Feb 10, 2022 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Monte Rosa Therapeutics, Inc. shares.
No Form 144 notices for Monte Rosa Therapeutics, Inc. are on file.